In this clinical setting, ADAMTS-13 is present at a normal level (see Table 3), sufficient to proteolyze in part UL-VWF multimers, at variance with the situation observed in canonical forms of thrombotic microangiopathies, where ADAMTS-13 is <6%. This evidence concerns the gene VWF and thrombotic microangiopathy.